Candel Therapeutics (CADL) Profit After Tax (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Profit After Tax data on file, last reported at -$29.5 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax fell 109.62% year-over-year to -$29.5 million; the trailing twelve-month figure through Dec 2025 stood at -$38.2 million (up 30.77% YoY), and the FY2025 full-year result was -$38.2 million, up 30.77% from the prior year.
• Profit After Tax slipped to -$29.5 million in Q4 2025, from -$11.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $7.4 million in Q1 2025 to a low of -$29.5 million in Q4 2025.
• A 5-year average of -$9.3 million and a median of -$8.7 million in 2022 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax sank 906.86% in 2023 and soared 189.99% in 2025, its largest moves.
• Tracing CADL's Profit After Tax over 5 years: stood at $1.6 million in 2021, then plunged by 419.17% to -$5.1 million in 2022, then plunged by 117.9% to -$11.1 million in 2023, then retreated by 26.78% to -$14.1 million in 2024, then slumped by 109.62% to -$29.5 million in 2025.
• Business Quant data shows CADL's Profit After Tax at -$29.5 million in Q4 2025, -$11.3 million in Q3 2025, and -$4.8 million in Q2 2025.